These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 35900488)

  • 1. Effect of HER2 and Fascin expression on muscle-invasive bladder cancers: Classification by basaloid and luminal phenotypes.
    Arslan AI; Karabağ S; Akgül M
    Indian J Pathol Microbiol; 2022; 65(3):604-609. PubMed ID: 35900488
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunohistochemical based molecular subtypes of muscle-invasive bladder cancer: association with HER2 and EGFR alterations, neoadjuvant chemotherapy response and survival.
    Helal DS; Darwish SA; Awad RA; Ali DA; El-Guindy DM
    Diagn Pathol; 2023 Feb; 18(1):11. PubMed ID: 36737799
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinicopathologic and Immunohistochemical Study of Combined Small Cell Carcinoma and Urothelial Carcinoma Molecular Subtype.
    Xiao GQ; Barrett MM; Yang Q; Unger PD
    Pathol Oncol Res; 2019 Jul; 25(3):889-895. PubMed ID: 29249035
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes.
    Kim MJ; Ro JY; Ahn SH; Kim HH; Kim SB; Gong G
    Hum Pathol; 2006 Sep; 37(9):1217-26. PubMed ID: 16938528
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of immunohistochemistry in the diagnosis of flat urothelial lesions: a study using CK20, CK5/6, P53, Cd138, and Her2/Neu.
    Jung S; Wu C; Eslami Z; Tanguay S; Aprikian A; Kassouf W; Brimo F
    Ann Diagn Pathol; 2014 Feb; 18(1):27-32. PubMed ID: 24321464
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Three-antibody classifier for muscle invasive urothelial carcinoma and its correlation with p53 expression.
    Olkhov-Mitsel E; Hodgson A; Liu SK; Vesprini D; Xu B; Downes MR
    J Clin Pathol; 2022 Nov; 75(11):766-771. PubMed ID: 34103388
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ductal invasive mammary carcinoma--clinicopathological prognostic factors related to immunohistochemical expression of hormonal receptors and Her2/neu oncoprotein.
    Recăreanu F; Simionescu C; Georgescu CV; Pirici E
    Rom J Morphol Embryol; 2011; 52(3 Suppl):1059-64. PubMed ID: 22119825
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fascin is a predictor for invasiveness and recurrence of urothelial carcinoma of bladder.
    Bi J; Chen X; Zhang Y; Li B; Sun J; Shen H; Kong C
    Urol Oncol; 2012 Sep; 30(5):688-94. PubMed ID: 20888270
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intratumoral Switch of Molecular Phenotype and Overall Survival in Muscle Invasive Bladder Cancer.
    De Carlo C; Valeri M; Rudini N; Zucali PA; Cieri M; Elefante GM; D'antonio F; Hurle R; Giordano L; Bressan A; Lazzeri M; Perrino M; Guazzoni G; Terracciano LM; Colombo P
    Cancers (Basel); 2022 Jul; 14(13):. PubMed ID: 35805028
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predicting outcomes in non-muscle invasive (Ta/T1) bladder cancer: the role of molecular grade based on luminal/basal phenotype.
    Rebola J; Aguiar P; Blanca A; Montironi R; Cimadamore A; Cheng L; Henriques V; Lobato-Faria P; Lopez-Beltran A
    Virchows Arch; 2019 Oct; 475(4):445-455. PubMed ID: 31240474
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunohistochemical assessment of basal and luminal markers in non-muscle invasive urothelial carcinoma of bladder.
    Rodriguez Pena MDC; Chaux A; Eich ML; Tregnago AC; Taheri D; Borhan W; Sharma R; Rezaei MK; Netto GJ
    Virchows Arch; 2019 Sep; 475(3):349-356. PubMed ID: 31300876
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fatty acid synthase, Her2/neu, and E2F1 as prognostic markers of progression in non-muscle invasive bladder cancer.
    Abdelrahman AE; Rashed HE; Elkady E; Elsebai EA; El-Azony A; Matar I
    Ann Diagn Pathol; 2019 Apr; 39():42-52. PubMed ID: 30684846
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Progression of urothelial carcinoma in situ of the urinary bladder: a switch from luminal to basal phenotype and related therapeutic implications.
    Barth I; Schneider U; Grimm T; Karl A; Horst D; Gaisa NT; Knüchel R; Garczyk S
    Virchows Arch; 2018 May; 472(5):749-758. PubMed ID: 29654370
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bladder Tumor Subtype Commitment Occurs in Carcinoma
    Wullweber A; Strick R; Lange F; Sikic D; Taubert H; Wach S; Wullich B; Bertz S; Weyerer V; Stoehr R; Breyer J; Burger M; Hartmann A; Strissel PL; Eckstein M
    Cancer Res; 2021 Mar; 81(6):1552-1566. PubMed ID: 33472889
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of basal and luminal cytokeratins in breast cancer and their correlation with clinicopathological prognostic variables.
    Mohammadizadeh F; Naimi A; Rajabi P; Ghasemibasir H; Eftekhari A
    Indian J Med Sci; 2009 Apr; 63(4):152-62. PubMed ID: 19414985
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic stratification of muscle invasive urothelial carcinomas using limited immunohistochemical panel of Gata3 and cytokeratins 5/6, 14 and 20.
    Jangir H; Nambirajan A; Seth A; Sahoo RK; Dinda AK; Nayak B; Kaushal S
    Ann Diagn Pathol; 2019 Dec; 43():151397. PubMed ID: 31494492
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of a basal-like subtype of breast ductal carcinoma in situ.
    Livasy CA; Perou CM; Karaca G; Cowan DW; Maia D; Jackson S; Tse CK; Nyante S; Millikan RC
    Hum Pathol; 2007 Feb; 38(2):197-204. PubMed ID: 17234468
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Profiling the Biological Characteristics and Transitions through Upper Tract Tumor Origin, Bladder Recurrence, and Muscle-Invasive Bladder Progression in Upper Tract Urothelial Carcinoma.
    Shigeta K; Matsumoto K; Tanaka N; Mikami S; Kosaka T; Yasumizu Y; Takeda T; Mizuno R; Kikuchi E; Oya M
    Int J Mol Sci; 2022 May; 23(9):. PubMed ID: 35563543
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comedo-DCIS is a precursor lesion for basal-like breast carcinoma: identification of a novel p63/Her2/neu expressing subgroup.
    Shekhar MP; Kato I; Nangia-Makker P; Tait L
    Oncotarget; 2013 Feb; 4(2):231-41. PubMed ID: 23548208
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic significance of basal-like phenotype and fascin expression in node-negative invasive breast carcinomas.
    Rodríguez-Pinilla SM; Sarrió D; Honrado E; Hardisson D; Calero F; Benitez J; Palacios J
    Clin Cancer Res; 2006 Mar; 12(5):1533-9. PubMed ID: 16533778
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.